TRCT
MBX

Tower Research Capital (TRC)’s MBX Biosciences MBX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.1K Sell
1,411
-2,005
-59% -$68.2K ﹤0.01% 2898
2025
Q4 		$108K Buy
3,416
+2,149
+170% +$52.1K ﹤0.01% 1893
2025
Q3 		$22.2K Sell
1,267
-843
-40% -$11.3K ﹤0.01% 3225
2025
Q2 		$24.1K Buy
2,110
+745
+55% +$7.59K ﹤0.01% 3577
2025
Q1 		$10.1K Buy
1,365
+562
+70% +$5.94K ﹤0.01% 3679
2024
Q4 		$14.8K Buy
803
+649
+421% +$13.8K ﹤0.01% 3444
2024
Q3 		$4K Buy
+154
New +$3.52K ﹤0.01% 4710

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Tower Research Capital (TRC)'s MBX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its MBX Biosciences (MBX) stake by 59% in Q1 2026, selling an estimated $68.2K and leaving 1,411 shares worth $42.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2898.

Tower Research Capital (TRC) first reported a position in MBX in Q3 2024 and has held it in 7 quarters since. The position peaked at $108K in Q4 2025. 157 funds tracked by Wall St. Rank hold MBX as of Q1 2026.

  • Tower Research Capital (TRC) held 1,411 shares of MBX Biosciences worth $42.1K as of Q1 2026.
  • Tower Research Capital (TRC) sold 2,005 MBX Biosciences shares in Q1 2026, an estimated $68.2K.
  • MBX Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2898 holding.
  • Tower Research Capital (TRC) first reported a position in MBX Biosciences in Q3 2024 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s MBX Biosciences position peaked at $108K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.